- 1 Impact of COVID-19 on diabetes mellitus outcomes and care in sub-Saharan Africa:
- 2 A scoping review.
- Wenceslaus Sseguya^{1,4*}, Silver Bahendeka^{3,4}, Sara MacLennan¹, Nimesh Mody² & Aravinda
- 4 Meera Guntupalli¹,
- ¹ Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, United Kingdom
- 6 ² Institute of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom
- 7 Mother Kevin Postgraduate Medical School, Uganda Martyrs University, Kampala, Uganda
- 8 ⁴ Department of Internal Medicine, St Francis Hospital Nsambya, Kampala, Uganda
- 9 *Corresponding author
- 10 Email: w.sseguya.21@abdn.ac.uk (WS)

Abstract

11

12

13

14

15

16

17

18

19

20

21

22

23

27

28

29

30

31

32

33

34

Background

The COVID-19 pandemic impacted diabetes mellitus clinical outcomes and chronic care

globally. However, little is known about its impact in low-resource settings such as sub-Saharan

Africa. Hence, to address this, we systematically conducted a scoping review to explore the

COVID-19 impact on diabetes outcomes and care in countries of sub-Saharan Africa.

Methods

We applied our search strategy to PubMed, Web of Science, CINAHL, African Index Medicus,

Google Scholar, Cochrane Library, Scopus, Science Direct, ERIC and Embase to obtain relevant

articles published from January 2020 to March 2023. Two independent reviewers were involved

in the screening of retrieved articles. Data from eligible articles were extracted from

quantitative, qualitative and mixed methods studies. Numerical data were summarised using

descriptive statistics, while a thematic framework was used to categorise and identify themes

24 for qualitative data.

25 Results

We found 42 of the retrieved 360 articles eligible, mainly from South Africa, Ethiopia and

Ghana (73.4%). COVID-19 increased the risk of death (OR 1.30 – 9.0, 95% CI), hospitalisation

(OR 3.30 – 3.73: 95% CI), and severity (OR: 1.30-4.05, 95% CI) in persons with diabetes

mellitus. COVID-19 also increased the risk of developing diabetes mellitus in hospitalised cases.

The pandemic, on the other hand, was associated with disruptions in patient self-management

routine and diabetes mellitus care service delivery. Three major themes emerged, namely, (i)

patient-related health management challenges, (ii) diabetes mellitus care service delivery

challenges, and (iii) reorganisation of diabetes mellitus care delivery.

Conclusion

- 35 COVID-19 increased mortality and morbidity among people living with diabetes mellitus. In
- addition, the COVID-19 pandemic worsened diabetes mellitus care management. Sub-Saharan
- 37 African countries should, therefore, institute appropriate policy considerations for persons with
- 38 diabetes mellitus during widespread emergencies.

Introduction

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

Global evidence suggests that the coronavirus disease 2019 (COVID-19) resulted in a worldwide surge in mortality, morbidity, and disability, which predominantly occurred among older adults and individuals with chronic disease conditions [1,2]. COVID-19 has been reported to worsen diabetes mellitus (DM) clinical outcomes in particular, and DM care in general generally [3-8]. However, very little in this context is known in low- and middle-income countries, particularly in sub-Saharan Africa (SSA). While SSA is estimated to be host to 24 million of the estimated 537 million people with DM globally, the region records the highest rate of DM-related premature mortality [9]. Furthermore, SSA is predicted to experience the highest rate of rise in DM prevalence than any other region by 2040, depicting the magnitude of a growing threat [9]. DM is an underresearched area in SSA, which may underlie the limited understanding of the scale of the COVID-19 impact on persons living with DM (PLWD) and related vulnerabilities within the region. To address this gap, we carried out a scoping review to assimilate knowledge in this area that supports evidence-based policy consideration and stimulates future research in this field in SSA. We, therefore systematically conducted a scoping review of published qualitative, quantitative and mixed methods literature to explore the COVID-19 impact on DM outcomes and care in SSA. Our scoping review aimed to: (i) identify and characterise impact of COVID-19 infection on clinical outcomes of DM; (ii) describe DM care aspects that were impacted by the COVID-19 pandemic; and (iii) identify existing gaps in knowledge and research.

Methods

Study design

62 We report our scoping review in line with the Preferred Reporting Items for Systematic Reviews

and Meta-analyses extension for Scoping Reviews (PRISMA-ScR) (S1 PRISMA-ScR Checklist).

The initial protocol for this scoping review is reposited with Open Science Framework

[https://doi.org/10.17605/OSF.IO/9JCKF].

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

Data sources and search strategy

We searched ten electronic databases, i.e., PubMed, Web of Science, Cumulative Index to Nursing and Allied Health Literature (CINAHL), African Index Medicus, Google Scholar, Cochrane Library, Scopus, Science Direct, Education Resource Information Centre (ERIC) and Embase. We defined our search strategy guided by the SPIDER (Sample population, Phenomenon of Interest, Design, Evaluation and Research type) framework as outlined by Cooke et al. [10] to identify relevant literature from qualitative and mixed methods studies. Additionally, to capture relevant literature from quantitative studies, we enriched our search strategy by incorporating appropriate elements of the PICO (Population, Intervention, Comparison and Outcome) framework [11]. The detailed search strategy applied to all citation databases with their respective search strings is provided as supplementary material (S2 Search strategy). A search across all databases was initially conducted in May 2022 and later updated using the same search strategy in March 2023 to include any relevant records published between the two periods. This also opened up possibilities for including studies with data on various 'waves' of COVID-19 infection and emerging interventions as the pandemic progressed. All retrieved records were merged into a single MS[®] Excel file for subsequent removal of duplicate records and screening.

Selection criteria

The retrieved records were screened for eligibility through two stages, i.e., an initial review of article title and abstract and a subsequent full-text review of articles to be considered in final inclusion. An initial screening for the title and abstract was independently conducted by WS

89

96

97

99

101

104

105

106

109

111

and AMG and reviewed by SB, who also resolved any disagreements in screening decisions. 88 The same approach was applied for full-text screening. We defined agreement as a matching decision independently held by the reviewers involved in the screening process. 90 The inclusion criteria were (i) articles from any country listed under SSA by the World Bank in 91 2021 [12], (ii) articles focusing on or concerning DM and COVID-19, (ii) peer-reviewed articles 92 and reports and (iv) published from 01 January 2020 - 22 March 2023. The exclusion criteria 93 were (i) no full-text availability, (ii) articles not published in the English language, (iii) non-94 human studies, (iv) reviews, (v) articles with irrelevant scope, (vi) duplicate articles, and (vii) articles published as multicountry studies involving countries outside SSA but without 95 disaggregation of country-specific data (Fig 1). Data extraction and management 98 Data variables of interest from the selected articles were extracted and charted in the extraction form. The data extraction form was developed by WS and reviewed by AMG, SB, and 100 SM. It was then tested with two randomly selected articles from each set of quantitative, qualitative, and mixed methods studies for appropriateness. Appropriate revisions were made 102 and continuously refined and updated throughout the data extraction process. Data extraction 103 and charting were conducted by WS and independently reviewed by AMG and SB during the extraction and charting phase. **Data synthesis** We used an inductive thematic approach to synthesise and collate findings of qualitative and mixed-methods studies and open-ended results of quantitative studies. 107 We used SPSS® version 27.0 (IBM Corp, Armonk: New York) to summarise findings from 108 quantitative studies as mean (SD), range (minimum and maximum), proportions and frequencies, where appropriate. Due to the variability in methodological designs of 110 interventions and outcome measures across studies, a meta-analysis was not performed.

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128 129 Results Selection and characteristics of included studies A total of 360 unique records were retrieved from database searches, 42 of which were eligible for final inclusion (Fig 1). Inter-reviewer reliability analysis using the Cohen's kappa showed substantial agreement between reviewers at title and abstract screening (k=0.626, p<0.01), and moderate agreement at full-text screening (k=0.545, p<0.01). The detailed description of information of the included studies is shown in Table 1. The included studies were all observational but dominated by cross-sectional design (69%), with sample sizes ranging from 18 [13] to 3,460,932 [14]. The studies were predominantly retrospective (66.7%) and published between 2021 and 2022 (85.7%). The majority originated in South Africa (40.5%) and were mainly hospital-based (83.3%) and employed quantitative methods (90.4%). The extracted data variables were, DM prevalence among COVID-19 cases, outcomes of DM related to COVID-19 and their predictors, patient-related health management aspects, DM care service delivery aspects, and organisation of DM care related to the pandemic.

Table 1: extraction of data from included studies.

| Study | Study design | Location and period (study timeline) | Sample | Phenomenon studied/intervent ion | Evaluation / outcome | Key findings |
|----------------------------|-------------------------------|--|--|---|---|--|
| Mash RJ, et al. | Observational cross-sectional | rural & urban district hospitals, South | 1,376 patients admitted | | ProportionOdds ratio | 1. 25.2% had diabetes (20.3% among rural) |
| [15] | study | Africa March 2020 - June 2020 | with COVID- 19 | | | Type 2 diabetes (AOR 1.84, 1.24 - 2.73, 95%CI) was independently associated with a higher risk of death. |
| | | (Retrospective) | | | | 73.2% (n=272) had uncontrolled diabetes (HbA1c>8%), 78.6% from rural hospitals |
| Dave JA, et al. [16] | Observational cohort | district persons hospitals, with | onset diabetes Predictors of | ProportionOdds ratio | 11.3% of the diabetes cases were newly diagnosed during the COVID- 19 episode. | |
| | | western Cape, South Africa March 2020 - July 2020 | diabetes diagnosed with COVID- 19 | hospitalization and death | | Diabetes had a high risk for COVID- 19 hospital admission (OR:3.73, 95%CI 3.53,3.94) and mortality (OR:3.01,95%CI: 2.76,3.28) |
| | | (Retrospective) | | | | Insulin use was associated with increased risk for hospitalisation (OR:1.39, 95% CI:1.24,1.57) and mortality (OR:1.49, 95% CI:1.27,1.74) |
| | | | | | Metformin was associated with reduced risk for hospitalisation (OR 0.662, 95% CI:0.55,0.71) and mortality (OR 0.77, 95% CI:0.64;0.92) | |
| | | | | | | Being male increased risk of COVID- |

| | | | | | | 19 hospitalisation (OR 1.41, 95%CI: 1.29,1.54) and mortality (OR 1.70, 95%CI: 1.51, 1.92) • Age per 5-year interval was |
|---|-------------------------|--|--|--|--|--|
| | | | | | | associated with increased risk of COVID-19 hospitalisation (OR 1.15, 95%CI: 1.13,1.17) and mortality (OR 1.33, 95%CI: 1.30,1.37) |
| Van Observationa Hoving Cohort DJ, et al. [17] | Observational Cohort | Rural and urban hospitals in South Africa | hospitalised comorbidities patients Proportion of | comorbidities | Proportion | Diabetes (19.2%) was among the common comorbidities in the admitted patients. |
| | | April 2020 - June 2020 (Retrospective) | admitted for COVID-19 investigatio n | persons with diabetes | | 37.5% of deaths occurred in persons with diabetes |
| Ratshikho pha E. et | pha E. et cross- | Urban hospitals, South Africa | South Africa health comorbidities workers Predictors of COVID-19 sev December 2021 | comorbidities | ProportionOdds ratio | 27.6% of COVID-19 cases had diabetes. |
| al. [18] | sectional study | March 2020 - December 2021 (Retrospective) | | COVID-19 severity | | comorbid diabetes (aOR: 1.3, 95%CI 1.2-1.5) was associated with a higher risk for disease severity. |
| Claassen N, et al. | Observational cross- | Urban hospital in Cape Town, | 568 admitted | characteristics of survivors and | ProportionOdds ratio | 51% of deaths occurred in patients with diabetes. |
| [19] | sectional study | South Africa April 2020 - August 2020 | with confirmed SARS-CoV2 | confirmed patients | | Diabetes was associated with a higher risk of death (OR 2.7, 95% CI: 1.8 - 3.9) |
| | | J | | | | 19% of deaths in patients with diabetes were new onset |
| Abraha HE, et al. | Observational cohort | hospitals in PCR posi | 2,617 RT- PCR positive | | ProportionRelative risk | 3.1% of all cases and 18.4% of severe cases had comorbid diabetes. |
| [20] | | Northern Ethiopia May 2020 - | COVID-19 • Predictors of mortality patients | | Diabetes was associated with higher in-hospital mortality among COVID- 19 patients (uRR: 7.73, 95% CI: | |

| | | October 2020 (Retrospective) | | | | 2.58-23.12 |
|----------------------------------|---|---|--|--|---|--|
| Kaswa R, et al. [21] | Observational cross- sectional study | Rural hospital, Eastern Cape South Africa March 2020 - July 2020 (Retrospective) | 242 Hospitalised adult (>=18years) with laboratory-confirmed COVID-19 | Characteristics of clinical outcomes | Proportion of comorbidity | Diabetes occurred in 36.8% of the cases Diabetes was the commonest comorbidity associated with higher mortality |
| Mbarga NF, et al. [22] | Observational cohort | Urban hospitals in Cameroon April 2020 - July 2020 (Prospective) | 313 Patients admitted with suspected or confirmed COVID-19 | Clinical characteristics of cases Predictors of COVID-19 severity | ProportionOdds ratio | 5.8% of cases had diabetes Diabetes was associated with increased COVID-19 severity (OR: 4.05, 95% CI 1.12,14.15; p=0.01) |
| Kwaghe VG, et al. [23] | Observational cross- sectional study | Urban hospital in Abuja, Nigeria March 2020 June 2020 (Retrospective) | 200 admitted COVID-19 patients | Characteristics of cases | Proportion | ■ 18.5% of the cases had diabetes |
| Leulsege d TW, et al. [24] | Observational case-control | Urban hospital in Ethiopia June 2020 - September 2020 (Retrospective) | COVID-19 admitted patients Case =49 (death) Controls = 98 (recovered) | Predictors of clinical outcomes | ProportionOdds ratio | Having diabetes was associated with higher death outcomes than those with no diabetes (53.3% vs 46.7%, p=0.001) Diabetes patients exhibited higher odds of dying compared to those with no diabetes (AOR:3.26, 95% CI:1.35,7.87), p=<0.01. |

| Brey Z, et al. [25] | | oss- community commectional setting in Cape healt | | chronic disease | EffectivenessChallenges and threats | 46.2% of the delivery target was achieved The intervention was affected by incomplete, outdated and missing patient records and failure to reach registered phone contacts. |
|-------------------------------|---|--|--|--|--|--|
| | | | | | | Perceived opportunities were improved relationships of community health workers with linkage facilities and improved risk factor tracking. Perceived threats were stigma |
| | | | | | | associated with home delivery |
| Abate HK, et al. [26] | Observational cross- sectional study | Rural and urban hospitals in Ethiopia August 2020 - September 2020 (Prospective) | type 2 ad diabetes ex | Predictors of adherence to exercise recommendations | ProportionOdds ratio | 26.4% only adhered to physical exercise recommendations. Rural residence was associated with higher odds of adherence to physical exercise recommendations (AOR: 1.95, 95% CI: 1.16,3.27, p<0.05) Being female was associated with higher odds of physical exercise |
| | | | | | | adherence (AOR: 1.86, 95%CI, 1.27- 2.72, <i>p<0.01</i>) |
| Bepouka BI, et al. [27] | Observational cohort | Urban hospital in Kinshasa, Democratic Republic of Congo | hospitalised patients with RT-PCR confirmed | Characteristics of cases Predictors of survival and mortality | ProportionSurvival rate | 17% of COVID-19 hospitalised patients had diabetes. Patients with diabetes had reduced COVID-19 survival, p=0.015 |
| | | March 2020 - June 2020 (Retrospective) | COVID-19 | | | |

| Boulle, et al. [14] | Observational cohort | Rural and urban hospitals in West Cape Province, South Africa March 2020 - June 2020 (Retrospective) | 3,460,932 patients with PCR- confirmed COVID-19 | Predictors of COVID-19 death | Hazard ratio | ■ Diabetes was associated with COVID-19 death with the risk of death increasing with higher HbA1c values: <7% (HR 1.44, 95% CI: 1.06-1.96, p=0.02), 7%<9% (HR 1.81, CI:1.39-2.35, p<0.001), ≥9% (HR 1.60, CI: 1.27-2.0, p<0.001) all vs those without diabetes. |
|----------------------------------|---|---|--|--|---|--|
| Poaty H, et al. [28] | Observational cross- sectional study | Urban hospital in The Congo March 2020 - August 2020 (Retrospective) | 30 patients with pre- existing diabetes infected with SARS- CoV-2 | Characteristics of COVID-19 death | ■ Proportion | Diabetes patients with COVID-19 had a mortality rate of 36.7% |
| Ikram AS & Pillay S. [29] | Observational cohort | Urban hospital in KwaZulu Natal, South Africa June 2020 - September 2020 (Retrospective) | 236 hospitalised patients >13years with laboratory- confirmed SARS-CoV 2 infection | Predictors of mortality | ProportionOdds ratio | 50% of those admitted with hyperglycaemia having no history of diabetes died 26.6% of those living with diabetes (pre-existing or newly diagnosed) died. patients presenting with admission hyperglycaemia had higher odds of death (OR:4.24, 95%CI:1.12-16) Patients with diabetes had higher odds of dying compared to those with diabetes (OR: 1.97, 95% CI:0.99-3.89) |
| Leulsege d TW, et al. [30] | Observational cross- sectional study | Urban hospital in Ethiopia June 2020 - August 2020 | admitted | Characteristics of casesPredictors of COVID-19 severity | ProportionOdds ratio | 16.6% of cases had diabetes. Diabetes had higher odds of COVID-19 severity than those who had no diabetes (AOR: 3.93, 95% CI: |

| | | (Prospective) | COVID-19 | | | 1.96,7.85)29.9% of the severe cases had diabetes |
|--|---|---|---|--|---|---|
| Leulsege d TW., et al. [31] | Observational cohort | Rural and urban hospitals in Ethiopia July 2020 - September 2020 (Prospective) | 1,345 patients admitted with RT-PCR confirmed COVID-19 | Characteristics of cases Predictors of recovery | ProportionOdds ratio | 13.7% of cases had diabetes. Diabetes had a higher median duration of recovery (15 days) than those with no diabetes. Having diabetes was associated with 45.1% (p=0.005) lower odds of achieving clinical recovery compared to those without diabetes (AOR=0.549, 95% CI:0.337,0.894; p=<0.05). |
| Adjei P, et al. [32] | Observational cross- sectional study | Urban hospital in Accra, Ghana April 2020 - June 2020 (Retrospective) | 50 hospital- admitted COVID-19 diagnosed patients | Clinical characteristics | Proportion | 42% of cases had diabetes.90.5% of those with complications had diabetes.23.8% of those with diabetes died |
| van der Westhuiz en JN, et al. [33] | Observational cross- sectional study | Rural hospital in Western Cape Province, South Africa June 2020 August 2020 (Retrospective) | 1,447 patients admitted with confirmed COVID-19 and pre- existing or newly diagnosed diabetes | Characteristics of casesPredictors of death | ProportionOdds ratio | 86.5% had HbA1c >7%, median (IQR): 10% (8-12%). Being male (OR=2.05, 95%CI=1.07,3.93) and on insulin (OR=2.25, 95% CI=1.05,4.85) was associated with higher odds of death |
| Delobelle AP, et al. [34] | Observational cross- sectional study | Urban primary settings in South Africa | Facility workers = 09 Community- | Appraisal of care and management | ■ Impact | Cancellation of routine non- communicable disease clinic services and chronic patient 'clubs' |

| | | October 2020 - November 2020 | based workers = | | | Reduced availability of healthcare workforce | |
|--------------------------------|-------------------------------|--|-----------------------------------|--|------------------------------|--|---|
| | | (Prospective) | 11 Patient with type 2 | | | Introduction of clinic booking for clinics that improved clinic congestion. | |
| | | | diabetes and other NCD = 08 | | | Home delivery of medication using community health workers was adopted to decongest health facilities | |
| | | | | | | Improved performance of community health workforce | |
| | | | | | | Patient stigma associated with patient home visits and deliveries. | |
| | | | | | | General increase in workload among the health workforce. | |
| | | | | | | General decrease in the number of NCD patients visiting the facility compared with prior to COVID-19 period. | |
| | | | | | | Higher proportion of patients with uncontrolled diabetes. | |
| Crankson S, et al. | Observational cross- | cross- in Ghana | 2,334 PCR confirmed | Characteristics of cases | | Comorbid diabetes occurred in 2% of patients | |
| [35] | sectional study | March 2020 - August 2021 | COVID-19 patients | Predictors of long COVID and hospitalisation | | Long COVID occurred in 4.3% of persons with diabetes | |
| | | (Retrospective) | | | | Diabetes was associated with longer LOS (B=1.37, 95% CI=0.99-1.88, p <0.05) | |
| Ephraim RKD, et al. [36] | Observational cross-sectional | Rural and urban hospitals in Cape Coast, | 157 diabetes patients | Characteristics of cases | Proportion | 57.3% of patients had known complications including retinopathy (36.3%) | |
| | study | study G | study Ghana | aged 20 years and | | | Family, friends and close relatives |

| | | June 2020 - September 2020 (Prospective) | over | | | were the popular form of social support (79.6%) for diabetes patients, followed by diabetes teams (61.2%) fellow patients with diabetes (61.2%), social media (56.7%) and work/school mates (52.9%) |
|--------------------------------|---|--|---|--|---|---|
| | | | | | | Reduced frequency of meals was reported in 42% of the patients |
| Habineza JC, et al. [37] | Observational cross- sectional study | Rural and urban communities in Rwanda | 52 young adults with type 1 diabetes | Pandemic experiences and challenges Coping mechanisms | Proportion Experiences | 80.8% reported a drop in family income; 57.7% reported a reduction in meal frequency; 43.1% reported reduced physical activity |
| | | June 2020 - September 2020 (Prospective) | | | | Hypoglycaemia was the major acute complication (87.5%) |
| | | | | | | Access to diabetes management supplies during the COVID-19 pandemic did not significantly differ from pre-COVID-19. |
| | | | | | | 81.8% increase in patients accessing healthcare by foot. |
| Baguma S, et al. | Observational cohort | Urban Hospital in Northern | 664 hospitalised | Characteristics of cases | ProportionOdds ratio | 34.4% of deaths occurred in patients with diabetes. |
| [38] | | Uganda March 2020 - October 2021 (Retrospective) | patients with confirmed COVID-19 | Predictors of mortality | | Diabetes was associated with higher odds of death compared to those who had no diabetes (AOR=9.014, 95% CI=1.726 - 47.067) |
| Iroungou BA, et al. [39] | Observational cross- sectional study | Urban hospital in Lebreville, Gabon March 2020 - June 2020 | 837 COVID- 19 hospitalised patients | Characteristics of severe COVID-19 | Proportion | 16.1% patients with a history of diabetes had severe COVID-19 |

| | | (Retrospective) | | | | |
|---|---|--|---|---|--------------|--|
| Awucha NE, et al. [40] | Observational cross- sectional study | Rural and urban community settings in Nigeria May 2020 - June 2020 (Prospective) | 374 persons aged 15 years and older | Impact on essential medicine access | ■ Proportion | 28.1% had a known history of diabetes The proportion of patients with difficulty in accessing essential medicines during the COVID-19 pandemic was significantly higher than before the pandemic (29.6% vs 5.6%, p<0.001) 52.2% decrease in hospital visits for medicines |
| Kaswa RP. & Meel B. [41] | Observational cross- sectional study | Urban hospital in Eastern Cape, South Africa July 2020 - January 2021 (Retrospective) | 100 patients who died of COVID-19 | Characteristics of COVID-19 deaths | ■ Proportion | ■ 37% of patients had diabetes |
| Usui R, Kanamori S, Aomori M. & Watabe S. [42] | Observational cross- sectional study | Rural and urban hospitals in Cote d'Ivoire March 2020 - July 2020 (Retrospective) | 67 COVID- 19 infected persons | Comorbidities associated with COVID-19 deaths | ■ Proportion | 45% of COVID-19 deaths occurred in patients with diabetes |
| Tagoe ET, Nonvigno n J, van Der Meer R, | Observational cross- sectional study | Rural and urban hospitals in Ghana November 2020 - February 2021 | 18 healthcare professional s and health facility administrato | COVID-19 impact on diabetes service delivery | ■ Impact | Themes: high medicine and service costs and medicine shortages (disruption in supply chain, rationing, increased pricing of medicines) |

| Megiddo I, & Godman B. [13] | | (Prospective) | rs | | poor patient information management (substandard anthropometric procedures, increase in records with missing data, misplacement of patient record files) |
|--|---|---|---|---|--|
| | | | | | few trained healthcare providers (COVID-19 treatment prioritisation, patient rejection of referrals, high patient load) |
| | | | | | low healthcare provider motivation (unsupportive management) |
| | | | | | service organisation challenges (extended patient reviews, clinic overcrowding, increased clinic waiting times) |
| | | | | | national health policy-related concerns (policy restrictions could not allow flexibility in planning and cost sharing) |
| Sikhosan a LM, Jassat W & Makatini | Observational cross- sectional study | Rural and urban hospitals in Gauteng, South Africa | 1,861 SARS CoV 2 admitted patients | characteristics ofProportion cases | 21.6% of cases had diabetes |
| Z. [43] | | March 2020 - March 2021 (Retrospective) | | | |
| Elijah MI, et al. [44] | Observational cohort | Rural and urban hospitals in Kenya March 2020 - April 2021 (Retrospective) | 1,792 admitted COVID-19 patients | Predictors of hospitalisation and survival Prevalence of diabetes comorbidity Predictors of Proportion Odds ratio Odds ratio Odds ratio | 5.4% cases had diabetes Diabetes was a significant predictor of ICU admissions (aOR: 3.30, 95%CI: 1.94 - 560, p<0.0001) Diabetes was significantly associated with less survival probability compared to those without diabetes |

| | | | | | | (p<0.0001) |
|-------------------------------|---|---|---|---|--|---|
| Hardy OY, et al. [45] | Observational cross- sectional study | Urban hospital in Ghana March 2020 - October 2020 (Retrospective) | 175 adult patients hospitalised with COVID- 19 | Prevalence of comorbid diabetesPredictors of hospitalisation | ProportionCorrelation | 36.6% patients had type 2 diabetes No significant difference in COVID-19 severity and duration of hospitalisation between patients with diabetes and those without |
| Huluka KD, et al. [46] | Observational cross- sectional study | Urban hospital in Addis Ababa, Ethiopia March 2020 - September 2020 (Retrospective) | 463 SARS CoV-2 positive patients aged ≥18 | Clinical characteristics of cases | Proportion | 20.7% of cases had diabetes. 33.1% of those who experienced severe COVID-19 had diabetes. 35.8% of COVID-19 deaths had diabetes |
| Nyasulu SP, et al. [47] | Observational cross- sectional study | Urban hospital in South Africa March 2020 - November 2020 (Prospective) | 413 ICU admitted COVID-19 patients aged ≥18 | Characteristics of cases and outcomes | Proportion | 51% of patients had comorbid diabetes. 66% of patients with comorbid diabetes died |
| Solanki G, et al. [48] | Observational cross- sectional study | Rural and urban communities in South Africa March 2020 - June 2021 (Retrospective) | 188,292 private health insurance patients who tested positive for COVID-19 | Risk of hospitalisation | Odds ratio | Diabetes was associated with high risk for hospitalisation (OR 3.6; 95% CI 3.27 - 3.94) |
| Diarra M, et al. [49] | Observational cross- sectional study | Rural and urban hospitals in Senegal | 67,608 patients | Clinical characteristicsPredictors of mortality | ProportionRelative risk | 38.2% of cases had diabetes Relative risk for COVID-19 mortality was high in persons with comorbid diabetes (aRR=1.31, 95%CI=0.77- |

| | | March 2020 - October 2020 (Prospective) | | | | 2.23, <i>p<0.001</i>) |
|------------------------------|---|--|---|--|--|---|
| Tolossa T, et al. [50] | Observational cohort | Urban hospital western Ethiopia September 2020 - June 2021 (Retrospective) | 304 severe COVID-19 hospital- admitted patients | Clinical characteristics Predictors of onset diabetes | Proportion Hazard ratio | Incidence of diabetes among patients was 14.5%. Overall diabetes incidence rate at the end of follow-up (34 days) was 13.7/1,000 person day's observation (95% CI 10.2, 18.4) Median occurrence of diabetes was 11 days (95% CI: 7, 13) Risk of developing diabetes increased for the first 20 days and was constant thereafter (Kaplan-Meier survival estimate) Predictors of Diabetes included older age >41 years (AHR = 2.54, 95% CI: 1.15, 5.57, compared to <25 years, p=0.02), residing in urban settings (AHR = 2.49, 95% CI: 1.12, 5.52, compared to rural, p=0.02), being admitted within 48 hours of clinical manifestation compared to >48 hours (0.49, 95% CI: 0.23,0.96 ref.≤48 hrs, p=0.04) |
| David JN, et al. [51] | Observational cross- sectional study | Rural community in South Africa September 2020 - December 2020 (Prospective) | 544 type 2 diabetes patients attending routine care | Home delivery of medicines | Impact of home delivery | overall, HDM resulted in 0.46% reduction in HbA1c compared to non-HDM (p<0.01) Patients perceived HDM as timesaving. Patients perceived HDM as reducing exposure to coronavirus infection |

| Sane HA, et al. [52] | Observational cross- sectional study | Urban hospitals in Addis Ababa, Ethiopia September 2020 - September 2021 (Retrospective) | 244 COVID- 19-admitted patients with diagnosed diabetes | Prevalence of newonset diabetes Predictors of newonset diabetes | Proposition | s ratio | 31.1% of COVID-19 patients had onset Diabetes (95% CI: 25.4, 37.4) Males were more likely to develop new onset diabetes than females (aOR=2.9, 95%CI:1.2,7.1, p=0.018) |
|---|---|---|--|--|---------------|-----------|--|
| Jassat W, et al. [53] | Observational cross- sectional study | Rural and urban hospital in South Africa November 2020 - June 2021 (Prospective) | 3,217 COVID-19 hospitalised patients | Prevalence of diabetes | ■ Prop | | 26.6% had self-reported diabetes 7.3% of diabetes case were new diagnoses |
| Mengist B, Animut Z & Tolossa T. [54] | Observational cohort | Rural and urban hospitals in Northwest Ethiopia March 2020 - March 2021 (Retrospective) | 552 COVID- 19 hospitalised patients | Prevalence of diabetesPredictors of mortality | Propo Haza | ard ratio | 4% of patients had comorbid diabetes. patients with diabetes had 8 times higher hazard mortality than those without diabetes (AHR: 8.1, 95% Ci:2.9, 22.4, <i>p</i> <0.001) |

Prevalence and incidence of DM among COVID-19 cases

As shown in Table 2, comorbidity of DM and COVID-19 was very prevalent, with up to 51% pre-existing cases reported, and a mean (SD) figure of 23% (± 13.8). Prevalence as high as 31.1% was also reported for new-onset DM among COVID-19 hospitalised cases, and a high incidence rate of 37/1,000 person days [50].

Table 2: Studies reporting on different COVID-19 outcome variables.

| Outcome variable | Range or value | Study reference |
|--|-------------------|--|
| Comorbidity of DM and COVID-19 | | |
| Incidence of DM in COVID-19 cases (per 1,000-person day's observation) | 13.7 | [50] |
| Prevalence of new-onset DM among COVID-19 cases | 7.3% - 31.1% | [16,50,52,53] |
| Prevalence of DM among COVID-19 cases* | 2.0% - 51.0% | [15–18,20–23,30– 32,35,38,40,43,45–47,49,53– 56] |
| COVID-19-related outcomes in DM patients | | |
| Proportion of DM deaths attributed to COVID-19 | 5.3% - 66% | [17,19,24,28,29,32,33,42,46,47] |
| DM risk for COVID-19 mortality (odds ratio, 95% CI)** | 1.30 - 9.0 | [14–16,19,20,24,38,49,54] |
| Proportion of DM hospitalisation attributed to COVID-19*** | 17% | [27] |
| DM risk for COVID-19 hospitalisation (odds ratio, 95% CI)** | 3.30 - 3.73 | [16,35,48] |
| Proportion of DM-related COVID-19 severity | 16.1% - 33.1% | [20,30,39,46] |
| DM risk for COVID-19 severity (odds ratio, 95% CI)** | 1.30 - 4.05 | [18,22,30] |
| Duration of hospitalisation of DM patients with COVID-19 | 4.7 - 15.0 days | [22,31] |
| Proportion of PLWD experiencing COVID-19 complications | 4.3% - 90.5% | [32,35] |
| Predictors of COVID-19-related clinical outcomes | | |
| in DM Predictors of COVID-19 mortality in PLWD (odds ratio, 95% CI) | | |
| Age (per 5-year ageing interval) | 1.13 - 1.37 | [16] |
| Gender (Male) | 1.50 - 2.04 | [16,18,33] |
| Medication (Insulin) | 1.49 - 2.25 | [16,33] |
| Glycaemic control (HbA1c≥7%) | 1.39 - 1.60 | [14] |
| Predictors of COVID-19 hospitalisation in PLWD (odds ratio, 95% CI) | | |
| Age (per 5-year ageing interval) | 1.13 - 1.17 | [16] |
| Gender (Male) | 1.29 - 1.54 | [16] |
| Medication (Insulin) | 1.24 - 1.57 | [16] |
| Predictors of new-onset DM in COVID-19 patients (odds ratio, 95% CI) | | |
| Age (>41years) | 1.15 - 5.57 | [50] |

| Gender (Male) | 1.2 - 7.1 | [52] |
|-------------------|-------------|------|
| Residence (Urban) | 1.12 - 5.52 | [50] |

^{*(}mean=23% \pm 13.8%); ** compared to those with no diabetes; *** figure reported from single studies without confidence interval; HbA1c: Glycated Haemoglobin; CI: confidence interval

COVID-19-related outcomes of DM and their predictors

As shown in Table 2, mortality, hospitalisation, severity, and complications were the major outcomes related to COVID-19 in DM. The proportions of COVID-19-attributed mortality [17,19,24,28,29,32,33,42,46,47], hospitalisation [27], and severity [20,30,39,46] for PLWD were noticeable to high across the studies. The major predictors of COVID-19-related mortality and hospitalisation in PLWD were age, gender, DM treatment, and glycaemic control. For every 5-year age interval , being male, insulin treatment and HbA1c ≥7.0% were independently associated with higher odds for both COVID-19-related mortality [14,16,18,33] and hospitalisation [16]. On the other hand, new-onset DM, defined as DM diagnosed in hospitalised COVID-19 patients with prior normoglycaemia, was associated with age over 41 years, male gender and urban residence [50,52].

Impact of the COVID-19 pandemic on DM care

Using an inductive thematic approach, we constructed three major themes from qualitative, mixed methods studies and open-ended quantitative results. The findings were thematically categorised as patient-related health management challenges, DM care service delivery challenges, and reorganisation of DM care delivery (S3 Themes). Table 3 presents a summary of studies that reported on each theme category.

Table 3: Studies reporting COVID-19 pandemic's impact on various aspects of DM care management.

| Major theme | Sub-theme | Reference |
|--|---|---------------|
| Patient-related health management challenges | Self-management challenges | [15,33,36,37] |
| - | Affordability challenges | [13,37] |
| | Health service accessibility challenges | [13,37,51] |
| DM care service delivery | Health workforce challenges | [13,34] |

| challenges | Healthcare infrastructure challenges | [13] |
|-----------------------|---|------------|
| | Health information challenges | [25] |
| | Medicines and medical supplies | [13] |
| Re-organisation of DM | Patient-level reorganisation of care access | [25,34,51] |
| care delivery | Clinic-level reorganisation of management | [34] |
| | Community-level re-organisation of community health worker services | [25,34,51] |

Patient-related health management challenges

The three sub-themes that emerged under patient-related health management challenges were, self-management challenges, affordability challenges, and health service accessibility challenges. Self-management challenges reported among PLWD during the COVID-19 pandemic include reduced daily meal frequency [36,37], inadequate physical activity [26,37], and worsening glycaemic control [15,33,34]. Affordability challenges were related to increased costs of medicines [13] and reduced individual or household income [37]. PLWD also experienced health service accessibility challenges reported as increased clinic waiting time [13] and limited transport means to healthcare facilities [16,51]. Type 1 DM-specific challenges were limited food access, reduced affordability of living costs and accessibility of DM care services [37].

DM care service delivery challenges

Four sub-themes emerged under DM care delivery challenges, namely, health workforce challenges [13,34], healthcare infrastructure challenges [13,34], health information management challenges [13,25], and medicines and medical supplies [13]. Health workforce challenges were characterised by health workers' hesitancy towards work and the limited number of available DM specialists. This resulted in fewer active health workers at health facilities that increased workload [13,34]. At the same time, inadequate healthcare infrastructure limited available physical clinic space due to overwhelming patient numbers

[13,34]. The COVID-19 pandemic was also characterised by poor management of health information and medical records attributed to the heavy workload of health workers and the fear of the risk of cross-infection while collecting patient data [13,25]. Additionally, the pandemic worsened shortages of medicine and medical supplies at health facilities [13].

Reorganisation of DM care delivery

Four sub-themes, as shown in Table 3, were categorised under the reorganisation of DM care delivery as a result of the pandemic, namely, patient-level reorganisation of care access [25,34,51], clinic-level reorganisation in management [34], and community-level reorganisation of community health worker services [25,34,51]. The reorganisation of DM care delivery was in response to the challenges patients and healthcare facilities faced in accessing and delivering DM care services. The interventions included delivery of patient medicines to their homes through their community health workers [25,34,51], which addressed the risk of infection and mitigated the health facility accessibility challenges faced by patients during lockdowns [34]. At clinic level, routine non-communicable disease 'walk-in' clinics were replaced with a clinic booking system to manage patient appointments and control clinic patient numbers [34]. At the community level, community health workers were empowered to monitor and follow up on patients with non-communicable diseases, including DM, aimed at reducing the workload of health facility staff [25,34,51].

Discussion

Our scoping review of 42 articles highlighted COVID-19's impact on DM outcomes and care in SSA. It also lays down existing gaps in knowledge and research. To the best of our knowledge, this is the first systematic scoping review in SSA to investigate outcomes of DM with COVID-19 and the pandemic's effect on DM care. Our results show an inequitable representation in DM research in countries of SSA, with research outputs mainly contributed by South Africa.

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

Overall, our scoping review shows that COVID-19 increased the risk of mortality and hospitalisation in PLWD, which were associated with older age, poor glycaemic control, insulin use and being male. These risk factors have also been reported in the US [57], China [58] and the UK [59]. We observed that PLWD had up to nine times higher risk of death, more than three times higher risk of hospitalisation and up to four times higher risk for severity due to COVID-19 compared to those without DM. Notably, similar findings but with varying levels of mortality and morbidity have been reported in China and the USA by Kumar et al. [60]. They revealed higher odds of COVID-19-related mortality (2.16, 95% CI: 1.74-2.65) and severity (2.75, 95% CI: 2.09-3.62) in PLWD than those without DM. COVID-19's impact on DM clinical outcomes in SSA is significant and consistent with reports from the World Health Organization that indicate COVID-19 is deadlier in PLWD in Africa due to the region's characteristic poor glycaemic control [61,62]. Additionally, COVID-19 was associated with an increased risk of developing new-onset DM, especially among hospitalised COVID cases over 41 years, males and urban residents. We observed a DM incident rate of 13.7/1,000 person-days (the equivalent of 5/1,000 person-years) and a prevalence of new-onset DM of up to 31% among COVID-19 cases in SSA. This rate is, however, considerably lower than what has been reported in the US (23-83/1,000 person-years) [63], England (37.2/1,000 person-years) [64] and China (13.5/1,000 person-years) [65]. Whereas the variation in diabetes incidence among COVID-19 patients in SSA may be due to underreporting, COVID-19's epidemiological threat to the growing burden of DM in SSA needs to be tracked. As a pandemic, COVID-19 also impacted DM indirectly by causing disruptions in patient selfmanagement routines and delivery of DM services in SSA. As our scoping review highlights, this impact manifested through challenges posed by instituted COVID-19 restrictions. For PLWD, we observe that this negatively affected their dietary intake and engagement in physical activity and limited their access to healthcare. The experience in SSA was however, in marked contrast with reports from India [66] and the UK [67], which showed no notable negative COVID-19 impact on access to essential services among PLWD. This stark variation may be explained by the different countries' approaches to containing COVID-19, which in most SSA countries mainly targeted geographical containment, closure of non-essential services and prohibition of gatherings [68]. These unprecedented approaches created blockades to accessibility and affordability of various services, including health and social services [69–71]. On other grounds, there was a considerable shortage of health workforce, physical infrastructure and severe shortages of DM medicine and medical supplies. Whereas we acknowledge the preexistence of challenges in the health workforce, healthcare infrastructure and medical supplies in SSA before the COVID-19 pandemic, the magnitude might have worsened during the pandemic due to a shift in healthcare resource prioritisation toward COVID-19 [72][73][74][73,75]. Interestingly, we also observed from our scoping review that the pandemic presented some opportunities for DM care innovation. For instance, the delivery of medicine to patient homes implemented in South Africa reportedly reduced the risk of COVID-19 infection among PLWD, mitigated DM care access challenges and ensured continued chronic patient follow-up [40]. Home delivery of medicine has also been reported to improve treatment adherence among chronic disease patients in Rwanda, which shows its feasibility in other SSA countries [76]. The pandemic, as demonstrated in South Africa, has also evidenced the value of integrating chronic non-communicable disease prevention and care in the services of community health workers. Additionally, clinic booking systems introduced to replace walk-in clinics in public health centres were found to mitigate clinic overcrowding, reduce clinic waiting time, and provide better doctor-to-patient time. These changes in the reorganisation of healthcare service delivery proved vital in addressing many challenges posed by the COVID-19 pandemic and offer lessons to policy and practice in future planning.

Gaps in knowledge and research

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

In our scoping review, we note various gaps in knowledge that can inform subsequent research. Firstly, there is a gap in the published literature on the use of guidelines for managing COVID-19 and DM in SSA countries, which would help evaluate their appropriateness for future similar occurrences. Secondly, the studies in our scoping review did not report on vaccine uptake or how the different 'waves' of COVID-19 infection influenced COVID-19 outcomes among PLWD. This would provide an understanding of the outcomes of PLWD across evolving pandemic dynamics and health system interventions. Exploiting research opportunities to address such gaps in knowledge can provide further and comprehensive understanding to shape appropriate post-pandemic DM care approaches and health system preparedness in addressing chronic care vulnerabilities during possible future pandemics.

Limitations

While this scoping review provides reliable information by scoping various research types and sources, there are some limitations. Firstly, our scoping review only included articles published in English. This may have limited studies published from non-English speaking countries within SSA; therefore, some relevant studies may have been missed. However, considering what was retrieved from most SSA countries, we predict this number to be likely minimal. Secondly, the included studies were dominated by three countries, which may limit the generalisation of findings to SSA. Thirdly, the studies were mainly conducted in the initial phase of the pandemic in 2020, indicating that changes experienced after that may render some findings unrepresentative of the post-2020 dynamics including the impact of emerging COVID-19 variants. Moreover, the limited disaggregation of data by studies in our scoping review, especially age, gender and type of DM, limited the drawing of specific conclusions and analyses. Finally, we only included peer-reviewed literature, which may have excluded some valuable literature sources such as manuscripts, institutional reports and archives.

Nevertheless, this scoping review provided critical information and insights on how COVID-19 impacted PLWD and healthcare systems in SSA.

Conclusions

COVID-19 increased mortality and morbidity among PLWD and the occurrence of DM. In addition, the pandemic worsened DM self-care and DM service delivery generally. Therefore, further research in SSA is needed to understand the disease syndemism of pandemics such as COVID-19 and DM to inform future management strategies and policy considerations.

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

References Wang H, Paulson KR, Pease SA, Watson S, Comfort H, Zheng P, et al. Estimating excess 1. mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21. Lancet. 2022;399: 1513-1536. doi:10.1016/S0140-6736(21)02796-3 2. Post LA, Argaw ST, Jones C, Moss CB, Resnick D, Singh LN, et al. A SARS-CoV-2 Surveillance System in Sub-Saharan Africa: Modeling Study for Persistence and Transmission to Inform Policy. J Med Internet Res. 2020;22: e24248. doi:10.2196/24248 3. Fu Y, Hu L, Ren H-W, Zuo Y, Chen S, Zhang Q-S, et al. Prognostic Factors for COVID-19 Hospitalized Patients with Preexisting Type 2 Diabetes. Merlotti D, editor. Int J Endocrinol. 2022;2022: 1–13. doi:10.1155/2022/9322332 4. Havden MR. An Immediate and Long-Term Complication of COVID-19 May Be Type 2. Diabetes Mellitus: The Central Role of β-Cell Dysfunction, Apoptosis and Exploration of Possible Mechanisms. Cells. 2020;9: 2475. doi:10.3390/cells9112475 5. Landstra CP, de Koning EJP, COVID-19 and Diabetes: Understanding the Interrelationship and Risks for a Severe Course. Front Endocrinol (Lausanne). 2021;12. doi:10.3389/fendo.2021.649525 6. Filip R, Gheorghita Puscaselu R, Anchidin-Norocel L, Dimian M, Savage WK. Global Challenges to Public Health Care Systems during the COVID-19 Pandemic: A Review of Pandemic Measures and Problems. J Pers Med. 2022;12: 1295. doi:10.3390/jpm12081295 7. Topkar V. Interactions Between Diabetes And Covid-19: A Scoping Review. Yale University, 2022. Available: https://elischolar.library.yale.edu/ysphtdl/2207?utm source=elischolar.library.yale.edu%

2Fysphtdl%2F2207&utm medium=PDF&utm campaign=PDFCoverPages

311 8. Khunti K, Aroda VR, Aschner P, Chan JCN, Del Prato S, Hambling CE, et al. The impact of the COVID-19 pandemic on diabetes services: planning for a global recovery. Lancet 312 Diabetes Endocrinol. 2022;10: 890-900. doi:10.1016/S2213-8587(22)00278-9 313 314 9. IDF. IDF Diabetes Atlas 10th Edition. Brussels; 2021. 10. Cooke A, Smith D, Booth A. Beyond PICO. Qual Health Res. 2012;22: 1435-1443. 315 316 doi:10.1177/1049732312452938 317 11. Richardson S, Wilson MC, Nishikawa J, Hayward RS. The well-built clinical question: a key to evidence-based decisions. ACP J Club. 1995;123. 318 12. 319 World Bank. FOCUS: Sub-Saharan Africa. 2021 [cited 22 Feb 2024]. Available: 320 https://openknowledge.worldbank.org/pages/focus-sub-saharan-africa 321 13. Tagoe ET, Nonvignon J, van Der Meer R, Megiddo I, Godman B. Challenges to the delivery of clinical diabetes services in Ghana created by the COVID-19 pandemic. J 322 323 Health Serv Res Policy. 2023;28: 58-65. doi:10.1177/13558196221111708 324 14. Boulle A, Davies M-A, Hussey H, Ismail M, Morden E, Vundle Z, et al. Risk Factors for 325 Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa. Clin Infect Dis. 2021;73: e2005-e2015. 326 doi:10.1093/cid/ciaa1198 327 Mash RJ, Presence-Vollenhoven M, Adeniji A, Christoffels R, Doubell K, Eksteen L, et al. 328 15. Evaluation of patient characteristics, management and outcomes for COVID-19 at district 329 hospitals in the Western Cape, South Africa: descriptive observational study. BMJ Open. 330 2021;11: e047016. doi:10.1136/bmjopen-2020-047016 331 Dave JA, Tamuhla T, Tiffin N, Levitt NS, Ross IL, Toet W, et al. Risk factors for COVID-332 16. 333 19 hospitalisation and death in people living with diabetes: A virtual cohort study from 334 the Western Cape Province, South Africa. Diabetes Res Clin Pract. 2021;177: 108925.

| 335 | | doi:10.1016/j.diabres.2021.108925 |
|--|-----|--|
| 336 | 17. | van Hoving DJ, Hattingh N, Pillay SK, Lockey T, McAlpine DJ, Nieuwenhuys K, et al. |
| 337 | | Demographics and clinical characteristics of hospitalised patients under investigation for |
| 338 | | COVID-19 with an initial negative SARS-CoV-2 PCR test result. African J Emerg Med. |
| 339 | | 2021;11: 429-435. doi:10.1016/j.afjem.2021.09.002 |
| 340 | 18. | Ratshikhopha E, Muvhali M, Naicker N, Tlotleng N, Jassat W, Singh T. Disease Severity |
| 341 | | and Comorbidities among Healthcare Worker COVID-19 Admissions in South Africa: A |
| 342 | | Retrospective Analysis. Int J Environ Res Public Health. 2022;19: 5519. |
| 343 | | doi:10.3390/ijerph19095519 |
| 344 | 19. | Claassen N, van Wyk G, van Staden S, Basson MMD. Experiencing COVID-19 at a large |
| 345 | | district level hospital in Cape Town: A retrospective analysis of the first wave. South |
| 346 | | African J Infect Dis. 2022;37. doi:10.4102/sajid.v37i1.317 |
| | | |
| 347 | 20. | Abraha HE, Gessesse Z, Gebrecherkos T, Kebede Y, Weldegiargis AW, Tequare MH, et |
| 347 348 | 20. | Abraha HE, Gessesse Z, Gebrecherkos T, Kebede Y, Weldegiargis AW, Tequare MH, et al. Clinical features and risk factors associated with morbidity and mortality among |
| | 20. | |
| 348 | 20. | al. Clinical features and risk factors associated with morbidity and mortality among |
| 348 349 | 20. | al. Clinical features and risk factors associated with morbidity and mortality among patients with COVID-19 in northern Ethiopia. Int J Infect Dis. 2021;105: 776–783. |
| 348 349 350 | | al. Clinical features and risk factors associated with morbidity and mortality among patients with COVID-19 in northern Ethiopia. Int J Infect Dis. 2021;105: 776–783. doi:10.1016/j.ijid.2021.03.037 |
| 348 349 350 351 | | al. Clinical features and risk factors associated with morbidity and mortality among patients with COVID-19 in northern Ethiopia. Int J Infect Dis. 2021;105: 776–783. doi:10.1016/j.ijid.2021.03.037 Kaswa R, Yogeswaran P, Cawe B. Clinical outcomes of hospitalised COVID-19 patients at |
| 348 349 350 351 352 | | al. Clinical features and risk factors associated with morbidity and mortality among patients with COVID-19 in northern Ethiopia. Int J Infect Dis. 2021;105: 776–783. doi:10.1016/j.ijid.2021.03.037 Kaswa R, Yogeswaran P, Cawe B. Clinical outcomes of hospitalised COVID-19 patients at Mthatha Regional Hospital, Eastern Cape, South Africa: A retrospective study. South |
| 348 349 350 351 352 353 | 21. | al. Clinical features and risk factors associated with morbidity and mortality among patients with COVID-19 in northern Ethiopia. Int J Infect Dis. 2021;105: 776–783. doi:10.1016/j.ijid.2021.03.037 Kaswa R, Yogeswaran P, Cawe B. Clinical outcomes of hospitalised COVID-19 patients at Mthatha Regional Hospital, Eastern Cape, South Africa: A retrospective study. South African Fam Pract. 2021;63. doi:10.4102/safp.v63i1.5253 |
| 348 349 350 351 352 353 | 21. | al. Clinical features and risk factors associated with morbidity and mortality among patients with COVID-19 in northern Ethiopia. Int J Infect Dis. 2021;105: 776–783. doi:10.1016/j.ijid.2021.03.037 Kaswa R, Yogeswaran P, Cawe B. Clinical outcomes of hospitalised COVID-19 patients at Mthatha Regional Hospital, Eastern Cape, South Africa: A retrospective study. South African Fam Pract. 2021;63. doi:10.4102/safp.v63i1.5253 Fouda Mbarga N, Epee E, Mbarga M, Ouamba P, Nanda H, Nkengni A, et al. Clinical |
| 348 349 350 351 352 353 354 355 | 21. | al. Clinical features and risk factors associated with morbidity and mortality among patients with COVID-19 in northern Ethiopia. Int J Infect Dis. 2021;105: 776–783. doi:10.1016/j.ijid.2021.03.037 Kaswa R, Yogeswaran P, Cawe B. Clinical outcomes of hospitalised COVID-19 patients at Mthatha Regional Hospital, Eastern Cape, South Africa: A retrospective study. South African Fam Pract. 2021;63. doi:10.4102/safp.v63i1.5253 Fouda Mbarga N, Epee E, Mbarga M, Ouamba P, Nanda H, Nkengni A, et al. Clinical profile and factors associated with COVID-19 in Yaounde, Cameroon: A prospective |

359 characteristics and outcome of the first 200 patients hospitalized with coronavirus disease-2019 at a treatment center in Abuja, Nigeria: a retrospective study. Pan Afr Med 360 J. 2022;41: 118. doi:10.11604/pamj.2022.41.118.26594 361 362 24. Leulseged TW, Maru EH, Hassen IS, Zewde WC, Chamiso NH, Abebe DS, et al. Predictors of death in severe COVID-19 patients at millennium COVID-19 care center in 363 Ethiopia: a case-control study. Pan Afr Med J. 2021;38. 364 365 doi:10.11604/pamj.2021.38.351.28831 25. Brey Z, Mash R, Goliath C, Roman D. Home delivery of medication during Coronavirus 366 disease 2019, Cape Town, South Africa: Short report. African J Prim Heal Care Fam Med. 367 368 2020;12. doi:10.4102/phcfm.v12i1.2449 26. Abate HK, Ferede YM, Mekonnen CK. Adherence to physical exercise recommendations 369 among type 2 diabetes patients during the COVID-19 pandemic. Int J Africa Nurs Sci. 370 2022;16: 100407. doi:10.1016/j.ijans.2022.100407 371 27. 372 Bepouka BI, Mandina M, Makulo JR, Longokolo M, Odio O, Mayasi N, et al. Predictors of 373 mortality in COVID-19 patients at Kinshasa University Hospital, Democratic Republic of the Congo (from March to June 2020). Pan Afr Med J. 2020;37. 374 doi:10.11604/pamj.2020.37.105.25279 375 28. Poaty H, Emergence Poaty G, NDziessi G, Godefroy Ngakeni E, Doukaga Makouka T, 376 377 Soussa Gadoua R, et al. Diabetes and COVID-19 in Congolese patients. Afr Health Sci. 2021;21: 1100-1106. doi:10.4314/ahs.v21i3.18 378 29. Ikram A, Pillay S. Hyperglycaemia, diabetes mellitus and COVID-19 in a tertiary hospital 379 380 in KwaZulu-Natal. J Endocrinol Metab Diabetes South Africa. 2022;27: 32-41. doi:10.1080/16089677.2021.1997427 381 Leulseged TW, Abebe KG, Hassen IS, Maru EH, Zewde WC, Chamiso NW, et al. COVID-382 30.

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

19 disease severity and associated factors among Ethiopian patients: A study of the millennium COVID-19 care center. Taghizadeh-Hesary F, editor. PLoS One. 2022;17: e0262896. doi:10.1371/journal.pone.0262896 31. Leulseged TW, Hassen IS, Maru EH, Zewsde WC, Chamiso NW, Bayisa AB, et al. Characteristics and outcome profile of hospitalized African patients with COVID-19: The Ethiopian context. Mossong J, editor. PLoS One. 2021;16: e0259454. doi:10.1371/journal.pone.0259454 32. Adjei P, Afriyie-Mensah J, J. Ganu V, Puplampu P, Opoku-Asare B, Dzefi-Tettey K, et al. Clinical characteristics of COVID-19 patients admitted at the Korle-Bu Teaching Hospital, Accra, Ghana. Ghana Med J. 2020;54: 33–38. doi:10.4314/gmj.v54i4s.6 33. Van der Westhuizen J-N, Hussey N, Zietsman M, Salduker N, Manning K, Dave JA, et al. Low mortality of people living with diabetes mellitus diagnosed with COVID-19 and managed at a field hospital in Western Cape Province, South Africa. South African Med J. 2021;111: 961. doi:10.7196/SAMJ.2021.v111i10.15779 34. Delobelle PA, Abbas M, Datay I, De Sa A, Levitt N, Schouw D, et al. Non-communicable disease care and management in two sites of the Cape Town Metro during the first wave of COVID-19: A rapid appraisal. African J Prim Heal Care Fam Med. 2022;14. doi:10.4102/phcfm.v14i1.3215 35. Crankson S, Pokhrel S, Anokye NK. Determinants of COVID-19-Related Length of Hospital Stays and Long COVID in Ghana: A Cross-Sectional Analysis. Int J Environ Res Public Health. 2022;19: 527. doi:10.3390/ijerph19010527 Ephraim RKD, Duah E, Nkansah C, Amoah S, Fosu E, Afrifa J, et al. Psychological impact 36. of COVID-19 on diabetes mellitus patients in Cape Coast, Ghana: a cross-sectional study. Pan Afr Med J. 2021;40: 76. doi:10.11604/pamj.2021.40.76.26834

407 37. Habineza JC, James S, Sibomana L, Klatman E, Uwingabire E, Maniam J, et al. Perceived impact of the COVID-19 pandemic on young adults with type 1 diabetes in Rwanda. Pan 408 Afr Med J. 2021;40. doi:10.11604/pamj.2021.40.252.28899 409 410 38. Baguma S, Okot C, Alema NO, Apiyo P, Layet P, Acullu D, et al. Factors Associated With 411 Mortality Among the COVID-19 Patients Treated at Gulu Regional Referral Hospital: A Retrospective Study. Front Public Heal. 2022;10. doi:10.3389/fpubh.2022.841906 412 413 39. Iroungou BA, Mangouka LG, Bivigou-Mboumba B, Moussavou-Boundzanga P, Obame-Nkoghe J, Nzigou Boucka F, et al. Demographic and Clinical Characteristics Associated 414 With Severity, Clinical Outcomes, and Mortality of COVID-19 Infection in Gabon. JAMA 415 416 Netw Open. 2021;4: e2124190. doi:10.1001/jamanetworkopen.2021.24190 Emmanuel Awucha N, Chinelo Janefrances O, Chima Meshach A, Chiamaka Henrietta J, 40. 417 Ibilolia Daniel A, Esther Chidiebere N. Impact of the COVID-19 Pandemic on Consumers' 418 419 Access to Essential Medicines in Nigeria. Am J Trop Med Hyg. 2020;103: 1630–1634. 420 doi:10.4269/ajtmh.20-0838 421 41. Kaswa RP, B Meel. A Study on the Characteristic Features of Covid-19 Deaths in a 422 Regional Hospital in Mthatha in the Eastern Cape, South Africa. Indian J Forensic Med 423 Toxicol. 2021;16: 1554–1559. doi:10.37506/ijfmt.v16i1.17723 42. Usui R, Kanamori S, Aomori M, Watabe S. Analysis of COVID-19 mortality in patients 424 425 with comorbidities in Côte d'Ivoire. J Public Health Africa. 2022;13. doi:10.4081/jphia.2022.1748 426 43. Sikhosana ML, Jassat W, Makatini Z. Characteristics of hospitalised COVID-19 patients 427 428 during the first two pandemic waves, Gauteng. South African J Infect Dis. 2022;37. doi:10.4102/sajid.v37i1.434 429 44. Elijah IM, Amsalu E, Jian X, Cao M, Mibei EK, Kerosi DO, et al. Characterization and 430

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

determinant factors of critical illness and in-hospital mortality of COVID-19 patients: A retrospective cohort of 1,792 patients in Kenya. Biosaf Heal. 2022;4: 330–338. doi:10.1016/j.bsheal.2022.06.002 45. Hardy YO, Libhaber E, Ofori E, Amenuke DAY, Kontoh SA, Dankwah JA, et al. Clinical and laboratory profile and outcomes of hospitalized COVID□19 patients with type 2 diabetes mellitus in Ghana – A single □center study. Endocrinol Diabetes Metab. 2023;6. doi:10.1002/edm2.391 46. Huluka DK, Etissa EK, Ahmed S, Abule HA, Getachew N, Abera S, et al. Clinical Characteristics and Treatment Outcomes of COVID-19 Patients at Eka Kotebe General Hospital, Addis Ababa, Ethiopia. Am J Trop Med Hyg. 2022;107: 252–259. doi:10.4269/ajtmh.21-1270 47. Nyasulu PS, Ayele BT, Koegelenberg CF, Irusen E, Lalla U, Davids R, et al. Clinical characteristics associated with mortality of COVID-19 patients admitted to an intensive care unit of a tertiary hospital in South Africa. Aouissi HA, editor. PLoS One. 2022;17: e0279565. doi:10.1371/journal.pone.0279565 48. Solanki G, Wilkinson T, Bansal S, Shiba J, Manda S, Doherty T. COVID-19 hospitalization and mortality and hospitalization-related utilization and expenditure: Analysis of a South African private health insured population. Kuo RN, editor. PLoS One. 2022;17: e0268025. doi:10.1371/journal.pone.0268025 49. Diarra M, Barry A, Dia N, Diop M, Sonko I, Sagne S, et al. First wave COVID-19 pandemic in Senegal: Epidemiological and clinical characteristics. Mossong J, editor. PLoS One. 2022;17: e0274783. doi:10.1371/journal.pone.0274783 50. Tolossa T, Lema M, Wakuma B, Turi E, Fekadu G, Mulisa D, et al. Incidence and predictors of diabetes mellitus among severe COVID-19 patients in western Ethiopia: a

455 retrospective cohort study. J Endocrinol Metab Diabetes South Africa. 2023;28: 42-48. doi:10.1080/16089677.2022.2144016 456 457 51. David NJ, Bresick G, Moodaley N, Von Pressentin KB. Measuring the impact of community-based interventions on type 2 diabetes control during the COVID-19 458 459 pandemic in Cape Town - A mixed methods study. South African Fam Pract. 2022;64. doi:10.4102/safp.v64i1.5558 460 52. Sane AH, Mekonnen MS, Tsegaw MG, Zewde WC, Mesfin EG, Beyene HA, et al. New 461 Onset of Diabetes Mellitus and Associated Factors among COVID-19 Patients in COVID-462 19 Care Centers, Addis Ababa, Ethiopia 2022. Kretchy I, editor. J Diabetes Res. 463 464 2022;2022: 1-9. doi:10.1155/2022/9652940 53. Jassat W, Mudara C, Vika C, Dryden M, Masha M, Arendse T, et al. Undiagnosed 465 comorbidities among individuals hospitalised with COVID-19 in South African public 466 467 hospitals. South African Med J. 2022;112: 747–752. 468 doi:10.7196/SAMJ.2022.v112i9.16417 54. Mengist B, Animut Z, Tolossa T. Incidence and predictors of mortality among COVID-19 469 470 patients admitted to treatment centers in North West Ethiopia; A retrospective cohort 471 study, 2021. Int J Africa Nurs Sci. 2022;16: 100419. doi:10.1016/j.ijans.2022.100419 55. Kaswa P, Meel B. A Study on the Characteristic Features of Covid-19 Deaths in a 472 473 Regional Hospital in Mthatha in the Eastern Cape, South Africa. Indian J Forensic Med Toxicol. 2022;16. doi:10.37506/ijfmt.v16i1.17723 474 56. Elijah IM, Amsalu E, Jian X, Cao M, Mibei EK, Kerosi DO, et al. Characterization and 475 476 determinant factors of critical illness and in-hospital mortality of COVID-19 patients: A retrospective cohort of 1,792 patients in Kenya. Biosaf Heal. 2022;4: 330–338. 477 doi:https://doi.org/10.1016/j.bsheal.2022.06.002 478

479 57. Chen U-I, Xu H, Krause TM, Greenberg R, Dong X, Jiang X. Factors Associated With 480 COVID-19 Death in the United States: Cohort Study. JMIR Public Heal Surveill. 2022;8: 481 e29343. doi:10.2196/29343 482 58. Xu PP, Tian RH, Luo S, Zu ZY, Fan B, Wang XM, et al. Risk factors for adverse clinical 483 outcomes with COVID-19 in China: a multicenter, retrospective, observational study. Theranostics. 2020;10: 6372–6383. doi:10.7150/thno.46833 484 485 59. Bhaskaran K, Bacon S, Evans SJ, Bates CJ, Rentsch CT, MacKenna B, et al. Factors associated with deaths due to COVID-19 versus other causes: population-based cohort 486 analysis of UK primary care data and linked national death registrations within the 487 488 OpenSAFELY platform. Lancet Reg Heal - Eur. 2021;6: 100109. doi:10.1016/j.lanepe.2021.100109 489 60. 490 Kumar A, Arora A, Sharma P, Anikhindi SA, Bansal N, Singla V, et al. Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. Diabetes Metab 491 492 Syndr Clin Res Rev. 2020;14: 535–545. doi:10.1016/j.dsx.2020.04.044 493 61. Burki T. COVID-19 and diabetes in Africa: a lethal combination. Lancet Diabetes 494 Endocrinol. 2022;10: 23. doi:10.1016/S2213-8587(21)00315-6 495 62. Fina Lubaki J-P, Omole OB, Francis JM. Glycaemic control among type 2 diabetes patients in sub-Saharan Africa from 2012 to 2022: a systematic review and meta-496 497 analysis. Diabetol Metab Syndr. 2022;14: 134. doi:10.1186/s13098-022-00902-0 498 63. Birabaharan M, Kaelber DC, Pettus JH, Smith DM. Risk of New-Onset Type 2 Diabetes Mellitus in 600,055 Persons after COVID-19: a cohort study. Diabetes, Obes Metab. 499 500 2022;24: 1176-1179. doi:10.1111/dom.14659 Tazare J, Walker AJ, Tomlinson LA, Hickman G, Rentsch CT, Williamson EJ, et al. Rates 501 64. of serious clinical outcomes in survivors of hospitalisation with COVID-19 in England: a 502

503 descriptive cohort study within the OpenSAFELY platform. Wellcome Open Res. 2022;7: 504 142. doi:10.12688/wellcomeopenres.17735.1 65. Xie Y, Al-Aly Z. Risks and burdens of incident diabetes in long COVID: a cohort study. 505 506 lancet Diabetes Endocrinol. 2022;10: 311-321. doi:10.1016/S2213-8587(22)00044-4 66. Madan J. Blonquist T. Rao E. Marwaha A. Mehra J. Bharti R. et al. Effect of COVID-19 507 508 Pandemic-Induced Dietary and Lifestyle Changes and Their Associations with Perceived 509 Health Status and Self-Reported Body Weight Changes in India: A Cross-Sectional Survey. Nutrients. 2021;13: 3682. doi:10.3390/nu13113682 510 67. O'Connell M, Smith K, Stroud R. The dietary impact of the COVID-19 pandemic. J Health 511 512 Econ. 2022;84: 102641. doi:10.1016/j.jhealeco.2022.102641 513 68. Haider N, Osman AY, Gadzekpo A, Akipede GO, Asogun D, Ansumana R, et al. Lockdown measures in response to COVID-19 in nine sub-Saharan African countries. BMJ Glob 514 515 Heal. 2020;5: e003319. doi:10.1136/bmjgh-2020-003319 516 69. Ssequya W, James S, Manfred B, Munyagwa M, Klatman E, Ogle G, et al. Impact of 517 COVID-19 pandemic on young persons with type 1 diabetes in western Uganda. 518 Manuscr Submitt Publ. 2021. 70. Kebirungi H, Mwenyango H. Impacts of COVID-19 Pandemic Lockdown on the 519 Livelihoods of Male Commercial Boda-Boda Motorists in Uganda. In: Laituri M, 520 521 Richardson RB, Kim J, editors. The Geographies of COVID-19: Geospatial Stories of a 522 Global Pandemic. Cham: Springer International Publishing; 2022. pp. 195–207. doi:10.1007/978-3-031-11775-6_16 523 524 71. Hrynick TA, Ripoll Lorenzo S, Carter SE. COVID-19 response: mitigating negative impacts on other areas of health. BMJ Glob Heal. 2021;6: e004110. doi:10.1136/bmjgh-525 526 2020-004110

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544


545

546

547

548

72. Uwizeyimana T, Hashim HT, Kabakambira JD, Mujyarugamba JC, Dushime J, Ntacyabukura B, et al. Drug supply situation in Rwanda during COVID-19: issues, efforts and challenges. J Pharm Policy Pract. 2021;14: 12. doi:10.1186/s40545-021-00301-2 73. Amu H, Dowou RK, Saah FI, Efunwole JA, Bain LE, Tarkang EE. COVID-19 and Health Systems Functioning in Sub-Saharan Africa Using the "WHO Building Blocks": The Challenges and Responses. Front Public Heal. 2022;10. doi:10.3389/fpubh.2022.856397 74. Moolla I, Hiilamo H. Health system characteristics and COVID-19 performance in highincome countries. BMC Health Serv Res. 2023;23: 244. doi:10.1186/s12913-023-09206-z 75. Ayanore MA, Amuna N, Aviisah M, Awolu A, Kipo-Sunyehzi DD, Mogre V, et al. Towards Resilient Health Systems in Sub-Saharan Africa: A Systematic Review of the English Language Literature on Health Workforce, Surveillance, and Health Governance Issues for Health Systems Strengthening. Ann Glob Heal. 2019;85. doi:10.5334/aogh.2514 76. Tran DN, Kangogo K, Amisi JA, Kamadi J, Karwa R, Kiragu B, et al. Community-based medication delivery program for antihypertensive medications improves adherence and reduces blood pressure. Weinrauch LA, editor. PLoS One. 2022;17: e0273655. doi:10.1371/journal.pone.0273655 Supporting information S1 PRISMA-ScR Checklist S2 Search strategy S3 Themes



<u>Fig.</u> 1: PRISMA-ScR diagram reporting outcomes of the systematic scoping review process.